BULKGLP RESEARCH LIBRARY
Retatrutide U.S. Legal Status for Research
Published
Retatrutide remains investigational and is not FDA approved. A particular research transaction depends on its actual intended use and the applicable shipment, import, and institutional requirements; a research label alone does not establish legality.
Status checked October 10, 2026.
Key points
- Intended use includes claims and distribution circumstances.
- The laboratory research shipment exemption has specific conditions.
- Compounding eligibility, import compliance, and analytical quality require separate evidence.
Intended use and research shipments
Under 21 CFR 201.128, objective intent can be evidenced by labeling, advertising, statements, product design or composition, and circumstances of distribution. “Research use only” (RUO) wording must be assessed alongside that wider evidence.
21 CFR 312.2(b)(3) provides an exemption from Part 312 requirements for drugs intended solely for in vitro tests or laboratory research animals when shipped under 21 CFR 312.160. Conditions include prescribed labeling, diligence that the recipient regularly conducts the relevant tests and will actually use the shipment for them, and recipient, date, quantity, and batch records retained for two years after shipment. This limited exemption does not waive other applicable laws.
Compounding boundaries
Sections 503A and 503B provide conditional exemptions for compounded drugs. Their bulk-substance eligibility rules differ, and meeting one condition does not satisfy the whole statute. FDA’s 503A and 503B analysis identifies retatrutide’s lack of an applicable USP/NF monograph, approved-drug component status, bulks-list eligibility, and relevant shortage-list eligibility. FDA’s current position is that retatrutide cannot be used in compounding under federal law.
Imports and institutional review
For material regulated as a drug or active pharmaceutical ingredient, FDA checks applicable import requirements, including registration, listing, application status, labeling, and manufacturing compliance. Entry information must accurately identify the material, manufacturer, and intended use. Applicable import alerts, state requirements, and institutional procurement or research approvals need their own review.
Chain of custody
Connect the supplier, lot identifier, original analytical report, receipt, and subsequent transfers in a traceable record. A certificate of analysis documents test results; it is not regulatory authorization. The verified quality reference explains how lot-linked evidence supports that documentation.